Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate thyrotropin releasing hormone (TRH) as a
treatment for cancer-related fatigue.
The central hypothesis of this pilot study is that TRH is more efficacious than placebo in
alleviating cancer-related fatigue in patients with breast or prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
UConn Health
Collaborators:
Hollfelder foundation Susan G. Komen Breast Cancer Foundation